Risk factors for acute kidney injury in visceral leishmaniasis (Kala-Azar)

American Journal of Tropical Medicine and Hygiene

Volumn 82, Issue 3, 2010, Pages 449-453

  Oliveira, Michelle J C ^a   Silva Jr , Geraldo B ^a   Abreu, Krasnalhia Lívia S ^a   Rocha, Natália A ^a   Garcia, Ana Valeska V ^a   Franco, Luiz F L G ^a   Mota, Rosa M S ^a   Libório, Alexandre B ^b   Daher, Elizabeth F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF FORTALEZA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG USE; FEMALE; GENDER; HOSPITAL ADMISSION; HUMAN; JAUNDICE; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; TERTIARY HEALTH CARE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; KIDNEY DISEASES; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; RISK FACTORS; YOUNG ADULT;

NASO HEXACANTHUS;

EID: 77949805126     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0571     Document Type: Article

References (30)

1. Herwaldt BL, 1999. Leishmaniasis. Lancet 354: 1191-1199.
2. Efstratiadis G, Boura E, Giamalis P, Mandata E, Leontsini M, Tsiaousis G, Memmos D, 2006. Renal involvement in a patient with visceral leishmaniasis Nephrol Dial Transplant 21: 235-236.
3. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD, 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
4. Camargo LB, Langoni H, 2006. Impact of leishmaniasis on public health. Trop Dis 12: 527-548.
5. Dantas-Torres F, Brandão-Filho SP, 2006. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo 48: 151-156.
6. Boakye DA, Wilson MD, Kweku M, 2005. A review of leishmaniasis in west Africa. Ghana Med J 39: 94-97.
7. Salgado Filho N, Ferreira TMAF, Costa JML, 2003. Involvement of the renal function in patients with visceral leishmaniasis (kala-azar). Rev Soc Bras Med Trop 36: 217-221.
8. Oliveira AL, Brustoloni YM, Fernandes TD, Dorval ME, Cunha RV, Bóia MN, 2009. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Trop Doct 39: 180-182.
9. Daher EF, Evangelista LF, Silva Junior GB, Lima RS, Aragão EB, Arruda GA, Galeano NM, Mota RM, Oliveira RA, Silva SL, 2008. Clinical presentation and renal evaluation of human visceral leishmaniasis (kala-azar): a retrospective study of 57 patients in Brazil. Braz J Infect Dis 12: 329-332.
10. Beltrame A, Arzese A, Camporese A, Rorato G, Crapis M, Tarabini-Castellani G, Boscutti G, Pizzolitto S, Calianno G, Matteelli A, Di Muccio T, Gramiccia M, Viale P, 2008. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B. J Travel Med 15: 358-360.
11. Navarro M, Bonet J, Bonal J, Romero R, 2006. Secondary amyloidosis with irreversible acute renal failure caused by visceral leishmaniasis in a patient with AIDS. Nefrologia 26: 745-746.
12. Rollino C, Bellis D, Beltrame G, Basolo B, Montemagno A, Bucolo S, Ferro M, Quattrocchio G, Coverlizza S, Quarello F, 2003. Acute renal failure in leishmaniasis. Nephrol Dial Transplant 18: 1950-1951.
13. Ricci Z, Cruz D, Ronco C, 2008. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 73: 538-546.
14. Lima Verde FA, Lima Verde IA, Silva Junior GB, Daher EF, Lima Verde EM, 2007. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study of 50 patients from Brazil. J Nephrol 20: 430-436.
15. Pisoni R, Wille KM, Tolwani AJ, 2008. The epidemiology of severe acute kidney injury. From BEST to PICARD, in acute kidney injury: new concepts Nephron Clin Pract 109: c188-c191.
16. Lima Verde FAA, Lima Verde FA, Daher EF, Santos GM, Sabóia Neto A, Lima Verde EM, 2009. Renal tubular dysfunction in human visceral leishmaniasis (kala-azar). Clin Nephrol 71: 492-500.
17. Weisinger JR, Pinto A, Velasquez GA, Bronstein I, Dessene JJ, Duque JF, Montenegro J, Tapanes F, de Rousse AR, 1978. Clinical and histological kidney involvement in human kalaazar. Am J Trop Med Hyg 2: 357-359.
18. Martinelli R, Lourenzo R, Rocha H, 1986. Absence of clinical abnormalities suggesting renal involvement during long-term course of visceral leishmaniasis. Rev Soc Bras Med Trop 19: 209-212.
19. Tafuri WL, Michalik MSM, Dias M, Genaro O, Leite VHR, Barbosa AJA, Bambirra EA, Costa CA, Melo MN, Mayrink W, 1989. Estudo ao microscópio óptico e eletrônico do rim de cães natural e experimentalmente infectados com Leishmania chagasi. Rev Inst Med Trop Sao Paulo 31: 139-145.
20. Prasad LS, Sen S, Ganguly SK, 1992. Renal involvement in kalaazar. Indian J Med Res 95: 43-46.
21. Polli A, Abramo F, Mancianti F, Nigro M, Pieri S, Bionda A, 1991. Renal involvement in canine leishmaniasis. A light microscopic, immunohistochemical and electron microscopic study. Nephron 57: 444-452.
22. Dutra M, Martinelli M, Carvalho EM, Rodrigues LE, Brito E, Rocha H, 1985. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 6: 22-27.
23. Duvic C, Nedelec G, Debord T, Herody M, Didelot F, 1999. Important parasitic nephropathies: update from the recent literature. Nephrologie 20: 65-74.
24. Chaigne V, Knefati Y, Lafarge R, Bronner J, McGregor B, Fouque D, Sabatier JC, 2004. A patient with visceral leishmaniasis and acute renal failure in necrotizing glomerulonephritis. Nephrologie 25: 179-183.
25. Ben Salem L, Khiari K, Turki S, Cherif L, Ali IH, Maazoun I, Ben Moussa F, el Younsi F, Ben Abdallah N, Ben Maïz H, 2003. Obstructive acute renal failure revealing visceral leishmaniasis in a diabetic patient. Nephrologie 24: 95-99.
26. Clevenberg P, Okome MN, Benoit S, Bendini JC, De Salvador F, Elbeze M, Cassuto E, Marty P, Dellamonica P, 2002. Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1 infected patient. Scand J Infect Dis 34: 546-547.
27. Berdichevski RH, Luis LB, Crestana L, Manero RC, 2006. Amphotericin B-related nephrotoxicity in low-risk patients. Braz J Infect Dis 10: 94-99.
28. Bagnis CI, Deray G, 2002. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transpl 13: 481-491.
29. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
30. Werneck GL, Batista MS, Gomes JR, Costa CH, 2003. Prognostic factors from visceral leishmaniasis in Teresina, Brazil. Infection 31: 174-177.